Pancreatic cancer survival extended by over a year with chemotherapy regimen

Bookmark and Share
Published: 4 Jun 2018
Views: 1701
Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Dr Conroy presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a phase III randomised trial in which patients with surgically resected pancreatic cancer were treated with mFOLFIRINOX.

Compared to those receiving the current standard of care, gemcitabine, trial participants had a median disease free survival of 21.6months v 12.8months, and a median overall survival of 54.4 months v 35 months.

For more on these findings, watch his interview with ecancer, or read news coverage here.

View the slides here.